Are the Currently Existing AntiâHuman Papillomavirus Vaccines Appropriate for the Developing World?

van Bogaert LJ

Are the Currently Existing Anti‑Human Papillomavirus Vaccines Appropriate for the Developing World?

Author(s):

van Bogaert LJ

Cervical cancer prevention is expected to be achieved by vaccination of girls 2â�?�?�?�?3 years before sexual debut, and cervical smear cytology followâ�?�?�?�?up. The existing human papillomavirus (HPV) vaccines target the lowâ�?�?�?�?risk 6 and 11, and the highâ�?�?�?�?risk 16 and 18 subtypes, the most common agents of anoâ�?�?�?�?genital preâ�?�?�?�?invasive and invasive lesions. We conducted the review by searching PubMed using the terms “HPV,” “HPV subtypes,” “developing world,” and “HPVâ�?�?�?�?vaccine” to retrieve articles published between 2000 and 2011. We focused on studies that were relevant to the developing world. The proposed vaccination policy is currently unachievable in the developing world because of the cost of the vaccine, the lack of adequate cytology and followâ�?�?�?�?up infrastructures. Moreover, the subtypes of HPV involved in cervical pathology, their associations, and natural history (clearance and persistence rates) differ from the industrialized world. Therefore, the current bivalent and quadrivalent antiâ�?�?�?�?HPV vaccines are unlikely to achieve their target in the developing world. It follows from published data that there is an obligation of the pharmaceutical industry and of the publicâ�?�?�?�?health policy makers not to embark on mass vaccination campaigns without thorough information and investigation of the local relevance.

Select your language of interest to view the total content in your interested language

Awards Nomination
20+ Million Readerbase